"Interferon beta-1a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068556
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500
|
| Concept/Terms |
Interferon beta-1a- Interferon beta-1a
- beta-1a, Interferon
- Interferon beta 1a
- 1a, Interferon beta
- beta 1a, Interferon
Avonex- Avonex
- Avonex Pen
- Pen, Avonex
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1a".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1a".
This graph shows the total number of publications written about "Interferon beta-1a" by people in this website by year, and whether "Interferon beta-1a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon beta-1a" by people in Profiles.
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.
-
Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon. Neurology. 2017 10 24; 89(17):e210-e213.
-
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ?-1a in MS. Neurology. 2016 Oct 04; 87(14):1464-1472.
-
PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr; 26(4):827-38.
-
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41.
-
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52.
-
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008 Sep; 16(9):1546-55.
-
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82.
-
An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis. Mult Scler. 2007 Apr; 13(3):343-7.
-
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 Mar 14; 66(5):678-84.